Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymosin alpha 1 adjuvant therapy for asthma control
ChiCTR-IIR-17011947Phase 4Recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Jan 2017
- Modality
- Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of thymosin alpha 1 in asthma (2 arms), sponsored by Shanghai Changzheng Hospital. Primary endpoints: ACQ-5 score, FEV1 percent predicted and 2 more. Started Jan 2017; status: recruiting.
02
Drugs
thymosin alpha 1
03
Conditions
asthma
Beyond the preview
Go deeper on ChiCTR-IIR-17011947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-17011947.